What is the efficacy and safety of using simvastatin plus ezetimibe to lower LDL cholesterol in patients with chronic kidney disease?
A study by the Cholesterol Treatment Trialists (CTT) Collaboration found that simvastatin plus ezetimibe had a positive effect on lowering LDL cholesterol in patients with chronic kidney disease. The results of the study showed that there was a significant reduction in major cardiovascular events and all-cause mortality after 1 year of treatment (Lancet, 2011). Furthermore, a meta-analysis of individual participant data from 28 randomised trials conducted by the CTT Collaboration found a significant reduction in major coronary events and all-cause mortality regardless of renal function (Lancet Diabetes Endocrinol, 2016). Therefore, it can be concluded that the use of simvastatin plus ezetimibe is effective and safe in patients with chronic kidney disease. 